



Recognized for Quality, Innovation and Growth

Cardiva Medical designs and develops vascular access management products that facilitate rapid hemostasis following diagnostic and interventional endovascular procedures. Our Company has been recognized for our medical accomplishments.



2018 Shingo Award Winner
World's Highest Standard for
Operational Excellence



**Where are the Low-Hanging Fruits for
Medical Device Manufacturers?***

**Finding Good Candidates for
Risk-Sharing Arrangements***

**Harry Liu, Ph.D., is the Practice Lead in Technology,
Health Advisory Services at the RAND Corporation*



Finding Value in Medical Technology*

**Carla Dunham RN, North Mississippi Medical Center, Tupelo, MS*



Best Proof of Value of an Innovation category in 2018

VASCADE® Performance Guarantee:
a Risk-Sharing Purchasing Program



AdvaMed panel presentations for Value

**John Russell, Cardiva Medical CEO, 2017 & 2018 MedTechCon*



2018 Inc. 5000 Fastest Growing US Private Companies

One of the Fastest Growing Private Companies in the US

VASCADE MVP[®]

VENOUS VASCULAR CLOSURE SYSTEM

Early Ambulation. Simple. Proven.

Patient Benefit¹

- Patients can ambulate hours earlier than with manual compression, improving both patient satisfaction and introducing the opportunity for post-AF ablation workflow efficiencies.
- Patients prefer VASCADE MVP^{®*}
 - +63% for duration (nominal p-value < 0.0001)
 - +36% for discomfort (nominal p-value = 0.001)
 - +25% for pain (nominal p-value = 0.001)
- Use of opioids reduced by 58% with VASCADE MVP^{®**} (nominal p-value = 0.001)

Technology (VASCADE MVP[®] 800-612C-10U)

- Simple to use
- Extravascular bioabsorbable femoral access closure system
- Combines Cardiva's proven proprietary collapsible disc technology and thrombogenic resorbable collagen
- Leaves no permanent components behind
- Built upon the established and clinically proven VASCADE[®] Vascular Closure System which has been used with over 250,000 patients.
- VASCADE MVP[®] is designed specifically for electrophysiology procedures



Clinical Data¹

(mean time points shown unless otherwise noted)

- Reduced median Time to Ambulation (TTA) by 64% (3.9 hours) (p-value < 0.0001)²
- Reduced Total Post-Procedure Time (TPPT) by 54% (3.7 hours) (p-value < 0.0001)³
- Reduced Time to Discharge Eligibility (TTDE) by 54% (3.4 hours) (p-value < 0.0001)³
- Reduced Time to Hemostasis (TTH) by 55% (7.6 minutes/site)*
- ZERO (0) major complications

* Nominal p-values by two-sided t-test, not pre-specified, however actual results imply superiority

** Nominal p-values by two-sided Fisher's exact test, not pre-specified, however actual results imply superiority

1. AMBULATE Clinical Trial Report

2. p-values from two-sided t-test for means, and two-sided Wilcoxon rank sum test for medians, unadjusted for stratification factor

3. p-value from two-sided test

CARDIVA
MEDICAL, INC.

P: 866.602.6099 F: 866.602.1795
customerservice@cardivamedical.com
www.CardivaMedical.com

2019© Cardiva Medical, Inc.
VASCADE is a registered
trademark of Cardiva Medical, Inc.
LIT4378 Rev B